Downloads
Abstract
Objectives: (1) Evaluate the efficacy of 4AC+4T regimen as adjuvant chemotherapy for stage II, IIIA breast cancer patients with axillary lymph node positive. (2) Describe toxicity of the regimen.
Methods: Retrospective and prospective descriptive longitudinal study, in 39 stage II-III breast cancer patients with lymph node positive underwent modified radical mastectomy and axillary lymph node dissection, treated with 4AC + 4T regimen at Ha Tinh General Hospital from January 2013 to June 2019.
Results: Overall survival was 83.6%. Disease-free survial was 75.6%. DFS and OS are inversely proportional to tumor size, the number of metastatic lymph nodes, ER and/PR positive have a better prognosis than ER/PR negative, stage II disease have better prognosis than stage IIIA (p<0.05). Toxicities of AC+4T: Leukopenia in 64.1% of patients, with 10,1% was grade 3, 4. Neutropenia in 61.5% of patients, with 7,6% was grade 3, 4. Hypopigmentation in 51.3% of patients, with 7,6% was grade 3, 4. Thrombocytopenia in 17.9% of patients. Transaminase elevation in 43.6% of patients, no seen grade 3, 4. Increased blood creatinine was only recorded at grade 1 at 5.1%. Vomiting and nausea 87%, stomatitis 30.8%, diarrhea 38.4%, muscle pain 87%, peripheral neuropathy 74.4% peripheral edema 38.5%.
Conclusion: The 4AC + 4T regimen shows high efficacy and a acceptable toxicity in the treatment of stage II, IIIA breast cancer with axillary lymph node positive.
References
Globocan (2018), Breast Cancer - Estimated Incidence, mortality and prevalence Worldwide 2018.
D’Orsi CJ, Sickles EA, Mendelson EB, Morris EA, et al (2013). American College of Radiology Breast Imaging Reporting and Data System BI-RADS, 5th ed, (Eds), American Colege of Radiology, Reston, VA, 5: 758-61.
Nguyễn Diệu Linh (2013). “Nghiên cứu điều trị ung thư vú giai đoạn II, IIIA bằng phác đồ hóa chất bổ trợ TAC và AC tại bệnh viện K”, Luận án tiến sỹ y học. Trường Đại Học Y Hà Nội: 87-89.
Đỗ Thị Kim Anh (2008), “Đánh giá kết quả điều trị hóa chất bổ trợ phác đồ 4 AC - 4 paclitaxel trên bệnh nhân ung thư vú giai đoạn II, III tại bệnh viên K” Luận văn thạc sĩ, Trường đại học Y Hà Nội.
Nguyễn Thị Sang (2016), “Đánh giá kết quả hóa trị bổ trợ phác đồ TAC trong bệnh ung thư vú giai đoạn II,III hạch nách dương tính tại Bệnh viện K”, Luận án tiến sĩ, Trường đại học Y Hà Nội.
U.S Department of Health and Human Service (2010). Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. . accessed 14 June 2019.
Phùng Thị Huyền (2016), “Đánh giá kết quả hóa trị bổ trợ kết hợp Tratuzumab trên bệnh nhân ung thư vú giai đoạn II, III ”, Luận án tiến sĩ, Trường đại học Y Hà Nội.
Perez E.A, Romond E.H, Suman V.J et al (2011). Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol Off J Am Soc Clin Oncol, 29(25): 3366-3373.
| Published | 11-01-2025 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 65 (2020) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.2020.65.6 | |
| Keywords | Ung thư vú, hóa trị bổ trợ 4AC + 4T, Bệnh viện đa khoa tỉnh Hà Tĩnh. Breast cancer, 4AC+4T adjuvant chemotherapy, Ha Tinh General Hospital |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2020 Journal of Clinical Medicine Hue Central Hospital